I-mab Biopharma (Hangzhou) Co., Ltd. announced that it will receive equity funding for $19 million from returning investor I-Mab on February 7, 2024. The transaction is expected to be close by the end of March 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.78 USD | -1.66% | +1.14% | -6.32% |
04-18 | Verastem Names John Hayslip as Chief Medical Officer | MT |
04-15 | I-Mab Announces Chief Medical Officer Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.32% | 144M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- IMAB Stock
- News I-Mab
- I-mab Biopharma Co., Ltd. announced that it expects to receive CNY 19 million in funding from I-Mab